TreeWAS – Variant ID: rs2534671

Hospitalization Episode Statistics (HES)

Self-Reported Statistics (SRS)

Hierarchical visualisation How to interpret this figure?

Click here to show this figure without filtering.

Click on a node to zoom (except terminal nodes).

Download this figure in format

Results table

Term	Risk posterior probability	No effect posterior probability	Protective posterior probability
E05.9 Thyrotoxicosis, unspecified	0.000	0.000	1.000
E05.0 Thyrotoxicosis with diffuse goitre	0.000	0.000	1.000
E10.9 Without complications	0.000	0.000	1.000
K90.0 Coeliac disease	0.000	0.000	1.000
L40.9 Psoriasis, unspecified	1.000	0.000	0.000
M45.X9 Ankylosing spondylitis (Site unspecified)	1.000	0.000	0.000
E05 Thyrotoxicosis [hyperthyroidism]	0.000	0.000	1.000
E10 Insulin-dependent diabetes mellitus	0.000	0.000	1.000
G35 Multiple sclerosis	0.000	0.000	1.000
E00-E07 Disorders of thyroid gland	0.000	0.000	1.000
Chapter IV Endocrine, nutritional and metabolic diseases	0.000	0.000	1.000
E10.3 With ophthalmic complications	0.000	0.000	1.000
L40 Psoriasis	1.000	0.000	0.000
E10-E14 Diabetes mellitus	0.000	0.000	1.000
L40.5 Arthropathic psoriasis	1.000	0.000	0.000
E27 Other disorders of adrenal gland	0.000	0.009	0.991
E27.1 Primary adrenocortical insufficiency	0.000	0.009	0.991
E20-E35 Disorders of other endocrine glands	0.000	0.010	0.990
E10.1 With ketoacidosis	0.000	0.014	0.986
M45 Ankylosing spondylitis	0.986	0.014	0.000
E10.2 With renal complications	0.000	0.014	0.986
E06 Thyroiditis	0.000	0.017	0.983
G35-G37 Demyelinating diseases of the central nervous system	0.000	0.018	0.982
G37 Other demyelinating diseases of central nervous system	0.000	0.021	0.979
M45.X0 Ankylosing spondylitis (Multiple sites in spine)	0.978	0.022	0.000
G37.9 Demyelinating disease of central nervous system, unspecified	0.000	0.027	0.973
K90 Intestinal malabsorption	0.000	0.034	0.966
K90.9 Intestinal malabsorption, unspecified	0.000	0.040	0.960
E10.4 With neurological complications	0.000	0.042	0.958
M35.0 Sicca syndrome [Sjogren]	0.000	0.049	0.951
E06.3 Autoimmune thyroiditis	0.000	0.052	0.948
E50-E64 Other nutritional deficiencies	0.000	0.065	0.935
I25 Chronic ischaemic heart disease	0.910	0.090	0.000
E53 Deficiency of other B group vitamins	0.000	0.091	0.909
E03 Other hypothyroidism	0.000	0.094	0.906
E06.9 Thyroiditis, unspecified	0.000	0.100	0.900
E14 Unspecified diabetes mellitus	0.000	0.107	0.893
I25.2 Old myocardial infarction	0.892	0.108	0.000
T39.1 4-Aminophenol derivatives	0.889	0.111	0.000
E53.8 Deficiency of other specified B group vitamins	0.000	0.117	0.883
E10.5 With peripheral circulatory complications	0.000	0.121	0.879
T39 Poisoning by nonopioid analgesics, antipyretics and antirheumatics	0.875	0.125	0.000
E27.8 Other specified disorders of adrenal gland	0.000	0.127	0.873
I25.1 Atherosclerotic heart disease	0.873	0.127	0.000
E03.9 Hypothyroidism, unspecified	0.000	0.128	0.872
L40.8 Other psoriasis	0.857	0.143	0.000
I25.8 Other forms of chronic ischaemic heart disease	0.854	0.146	0.000
T36-T50 Poisoning by drugs, medicaments and biological substances	0.852	0.148	0.000
E02 Subclinical iodine-deficiency hypothyroidism	0.000	0.150	0.850
M45.X2 Ankylosing spondylitis (Cervical region)	0.843	0.156	0.000
I20-I25 Ischaemic heart diseases	0.837	0.163	0.000
E20 Hypoparathyroidism	0.000	0.164	0.836
E27.2 Addisonian crisis	0.000	0.167	0.833
I24 Other acute ischaemic heart diseases	0.832	0.168	0.000
I25.9 Chronic ischaemic heart disease, unspecified	0.825	0.175	0.000
E14.3 With ophthalmic complications	0.000	0.182	0.818
E10.8 With unspecified complications	0.000	0.185	0.815
I25.3 Aneurysm of heart	0.814	0.186	0.000
I24.0 Coronary thrombosis not resulting in myocardial infarction	0.810	0.190	0.000
E05.8 Other thyrotoxicosis	0.000	0.192	0.808
T46 Poisoning by agents primarily affecting the cardiovascular system	0.807	0.193	0.000
G37.8 Other specified demyelinating diseases of central nervous system	0.000	0.205	0.795
L40.0 Psoriasis vulgaris	0.794	0.206	0.000
T44 Poisoning by drugs primarily affecting the autonomic nervous system	0.791	0.209	0.000
I24.8 Other forms of acute ischaemic heart disease	0.788	0.212	0.000
L40.4 Guttate psoriasis	0.787	0.213	0.000
T39.3 Other nonsteroidal anti-inflammatory drugs [NSAID]	0.784	0.216	0.000
M45.X6 Ankylosing spondylitis (Lumbar region)	0.777	0.223	0.000
E10.0 With coma	0.000	0.226	0.774
G37.3 Acute transverse myelitis in demyelinating disease of central nervous system	0.000	0.227	0.773
E10.6 With other specified complications	0.000	0.239	0.761
E40-E46 Malnutrition	0.000	0.250	0.749
I25.5 Ischaemic cardiomyopathy	0.745	0.255	0.000
I20 Angina pectoris	0.745	0.255	0.000
E27.3 Drug-induced adrenocortical insufficiency	0.000	0.255	0.745
T45 Poisoning by primarily systemic and haematological agents, not elsewhere classified	0.744	0.256	0.000
E14.6 With other specified complications	0.000	0.256	0.744
M35 Other systemic involvement of connective tissue	0.000	0.257	0.743
L40.1 Generalised pustular psoriasis	0.742	0.258	0.000
T46.4 Angiotensin-converting-enzyme inhibitors	0.742	0.258	0.000
T39.9 Nonopioid analgesic, antipyretic and antirheumatic, unspecified	0.738	0.262	0.000
L40.3 Pustulosis palmaris et plantaris	0.735	0.264	0.000
G36 Other acute disseminated demyelination	0.000	0.270	0.730
T47 Poisoning by agents primarily affecting gastro-intestinal system	0.729	0.270	0.000
T43 Poisoning by psychotropic drugs, not elsewhere classified	0.728	0.272	0.000
E51 Thiamine deficiency	0.000	0.272	0.727
E53.9 Vitamin B deficiency, unspecified	0.000	0.273	0.727
E20.9 Hypoparathyroidism, unspecified	0.000	0.274	0.726
E31 Polyglandular dysfunction	0.000	0.276	0.724
I20.0 Unstable angina	0.720	0.280	0.000
T44.7 Beta-Adrenoreceeptor antagonists, not elsewhere classified	0.719	0.281	0.000
E05.5 Thyroid crisis or storm	0.000	0.283	0.717
E05.4 Thyrotoxicosis factitia	0.000	0.283	0.717
E05.3 Thyrotoxicosis from ectopic thyroid tissue	0.000	0.283	0.717
E10.7 With multiple complications	0.000	0.283	0.717
E01 Iodine-deficiency-related thyroid disorders and allied conditions	0.000	0.283	0.717
E00 Congenital iodine-deficiency syndrome	0.000	0.283	0.717
L40.2 Acrodermatitis continua	0.717	0.283	0.000
E12 Malnutrition-related diabetes mellitus	0.000	0.283	0.717
I25.0 Atherosclerotic cardiovascular disease, so described	0.714	0.286	0.000
E25 Adrenogenital disorders	0.000	0.287	0.713
E27.5 Adrenomedullary hyperfunction	0.000	0.289	0.710
E27.0 Other adrenocortical overactivity	0.000	0.289	0.710
E35 Disorders of endocrine glands in diseases classified elsewhere	0.000	0.290	0.710
E32 Diseases of thymus	0.000	0.290	0.710
E30 Disorders of puberty, not elsewhere classified	0.000	0.290	0.710
M45.X8 Ankylosing spondylitis (Sacral and sacrococcygeal region)	0.707	0.293	0.000
M45.X7 Ankylosing spondylitis (Lumbosacral region)	0.707	0.293	0.000
M45.X5 Ankylosing spondylitis (Thoracolumbar region)	0.707	0.293	0.000
M45.X4 Ankylosing spondylitis (Thoracic region)	0.707	0.293	0.000
M45.X3 Ankylosing spondylitis (Cervicothoracic region)	0.707	0.293	0.000
M45.X1 Ankylosing spondylitis (Occipito-atlanto-axial region)	0.707	0.293	0.000
E14.5 With peripheral circulatory complications	0.000	0.293	0.707
E06.4 Drug-induced thyroiditis	0.000	0.295	0.704
E06.2 Chronic thyroiditis with transient thyrotoxicosis	0.000	0.295	0.704
E06.0 Acute thyroiditis	0.000	0.295	0.704
I24.9 Acute ischaemic heart disease, unspecified	0.703	0.297	0.000
R31 Unspecified haematuria	0.702	0.298	0.000
E61 Deficiency of other nutrient elements	0.000	0.298	0.702
G37.5 Concentric sclerosis [Balo]	0.000	0.298	0.702
G37.4 Subacute necrotising myelitis	0.000	0.298	0.702
G37.2 Central pontine myelinolysis	0.000	0.298	0.702
G37.1 Central demyelination of corpus callosum	0.000	0.298	0.702
G37.0 Diffuse sclerosis	0.000	0.298	0.702
E06.1 Subacute thyroiditis	0.000	0.304	0.696
E14.1 With ketoacidosis	0.000	0.305	0.695
K90.3 Pancreatic steatorrhoea	0.000	0.308	0.692
K90.2 Blind loop syndrome, not elsewhere classified	0.000	0.308	0.692
K90.1 Tropical sprue	0.000	0.308	0.692
T46.2 Other antidysrhythmic drugs, not elsewhere classified	0.688	0.312	0.000
E21 Hyperparathyroidism and other disorders of parathyroid gland	0.000	0.312	0.688
C81-C96 Malignant neoplasms, stated or presumed to be primary, of lymphoid, haematopoietic and related tissue	0.000	0.312	0.688
E05.1 Thyrotoxicosis with toxic single thyroid nodule	0.000	0.313	0.686
E14.2 Withrenal complications	0.000	0.314	0.686
E34 Other endocrine disorders	0.000	0.319	0.681
K90.8 Other intestinal malabsorption	0.000	0.320	0.679
C91 Lymphoid leukaemia	0.000	0.321	0.679
E07 Other disorders of thyroid	0.000	0.322	0.678
C81 Hodgkin's disease	0.000	0.323	0.677
E56 Other vitamin deficiencies	0.000	0.323	0.677
T45.0 Antiallergic and antiemetic drugs	0.676	0.324	0.000
E27.4 Other and unspecified adrenocortical insufficiency	0.000	0.326	0.674
C85 Other and unspecified types of non-Hodgkin's lymphoma	0.000	0.327	0.673
E14.8 With unspecified complications	0.000	0.328	0.672
T36 Poisoning by systemic antibiotics	0.672	0.328	0.000
E03.8 Other specified hypothyroidism	0.000	0.328	0.672
E64 Sequelae of malnutrition and other nutritional deficiencies	0.000	0.329	0.670
E63 Other nutritional deficiencies	0.000	0.329	0.670
E50 Vitamin A deficiency	0.000	0.329	0.670
E60 Dietary zinc deficiency	0.000	0.329	0.670
E59 Dietary selenium deficiency	0.000	0.329	0.670
E52 Niacin deficiency [pellagra]	0.000	0.329	0.670
M35.3 Polymyalgia rheumatica	0.000	0.337	0.663
T48 Poisoning by agents primarily acting on smooth and skeletal muscles and the respiratory system	0.663	0.337	0.000
C85.9 Non-Hodgkin's lymphoma, unspecified type	0.000	0.337	0.663
D69 Purpura and other haemorrhagic conditions	0.000	0.340	0.660
K90.4 Malabsorption due to intolerance, not elsewhere classified	0.000	0.340	0.660
E06.5 Other chronic thyroiditis	0.000	0.346	0.654
E26 Hyperaldosteronism	0.000	0.346	0.654
D69.3 Idiopathic thrombocytopenic purpura	0.000	0.347	0.653
E53.1 Pyridoxine deficiency	0.000	0.348	0.652
E53.0 Riboflavin deficiency	0.000	0.348	0.652
E03.5 Myxoedema coma	0.000	0.351	0.649
E03.4 Atrophy of thyroid (acquired)	0.000	0.351	0.649
E03.3 Postinfectious hypothyroidism	0.000	0.351	0.649
E15-E16 Other disorders of glucose regulation and pancreatic internal secretion	0.000	0.359	0.641
E14.7 With multiple complications	0.000	0.359	0.641
E14.0 With coma	0.000	0.359	0.641
C81.9 Hodgkin's disease, unspecified	0.000	0.359	0.641
E03.0 Congenital hypothyroidism with diffuse goitre	0.000	0.361	0.638
C91.1 Chronic lymphocytic leukaemia	0.000	0.362	0.638
D69.6 Thrombocytopenia, unspecified	0.000	0.362	0.638
I25.6 Silent myocardial ischaemia	0.636	0.363	0.000
T39.4 Antirheumatics, not elsewhere classified	0.627	0.373	0.000
T39.2 Pyrazolone derivatives	0.627	0.373	0.000
T46.1 Calcium-channel blockers	0.624	0.376	0.000
T43.5 Other and unspecified antipsychotics and neuroleptics	0.623	0.376	0.000
T43.3 Phenothiazine antipsychotics and neuroleptics	0.623	0.377	0.000
T45.1 Antineoplastic and immunosuppressive drugs	0.622	0.378	0.000
T44.3 Other parasympatholytics [anticholinergics and antimuscarines] and spasmolytics, not elsewhere classified	0.622	0.378	0.000
I25.4 Coronary artery aneurysm	0.618	0.382	0.000
T38 Poisoning by hormones and their synthetic substitutes and antagonists, not elsewhere classified	0.617	0.383	0.000
I23 Certain current complications following acute myocardial infarction	0.612	0.388	0.000
E29 Testicular dysfunction	0.000	0.388	0.611
T49 Poisoning by topical agents primarily affecting skin and mucous membrane and by ophthalmological, otorhinolarygological and dental drugs	0.611	0.389	0.000
T41 Poisoning by anaesthetics and therapeutic gases	0.611	0.389	0.000
E54 Ascorbic acid deficiency	0.000	0.390	0.609
C84 Peripheral and cutaneous T-cell lymphomas	0.000	0.392	0.608
T47.1 Other antacids and anti-gastric-secretion drugs	0.606	0.394	0.000
T44.9 Other and unspecified drugs primarily affecting the nervous system	0.603	0.397	0.000
T46.5 Other antihypertensive drugs, not elsewhere classified	0.601	0.399	0.000
M35.7 Hypermobility syndrome	0.000	0.399	0.601
E20.8 Other hypoparathyroidism	0.000	0.400	0.600
E20.1 Pseudohypoparathyroidism	0.000	0.400	0.600
E20.0 Idiopathic hypoparathyroidism	0.000	0.400	0.600
D69.5 Secondary thrombocytopenia	0.000	0.402	0.598
C90 Multiple myeloma and malignant plasma cell neoplasms	0.000	0.407	0.593
D69.4 Other primary thrombocytopenia	0.000	0.410	0.590
T37 Poisoning by other systemic anti-infectives and antiparasitics	0.590	0.410	0.000
E58 Dietary calcium deficiency	0.000	0.411	0.588
C81.1 Nodular sclerosis	0.000	0.417	0.583
T46.6 Antihyperlipidaemic and antiarteriosclerotic drugs	0.581	0.419	0.000
E51.2 Wernicke's encephalopathy	0.000	0.421	0.579
T46.9 Other and unspecified agents primarily affecting the cardiovascular system	0.578	0.421	0.000
T46.8 Antivaricose drugs, including sclerosing agents	0.578	0.421	0.000
T46.7 Peripheral vasodilators	0.578	0.421	0.000
T46.0 Cardiac-stimulant glycosides and drugs of similar action	0.578	0.421	0.000
T44.6 Alpha-Adrenoreceeptor antagonists, not elsewhere classified	0.578	0.422	0.000
C83 Diffuse non-Hodgkin's lymphoma	0.000	0.425	0.575
E14.4 With neurological complications	0.000	0.425	0.575
C91.4 Hairy-cell leukaemia	0.000	0.425	0.575
M35.1 Other overlap syndromes	0.000	0.428	0.572
E46 Unspecified protein-energy malnutrition	0.000	0.430	0.570
T43.6 Psychostimulants with abuse potential	0.568	0.432	0.000
T44.8 Centrally acting and afrenergic-neuron-blocking agents, not elsewhere classified	0.567	0.433	0.000
T44.5 Predominantly Beta-adrenoreceptor agonists, not elsewhere classified	0.567	0.433	0.000
T44.4 Predominantly Alpha-adrenoreceptor agonists, not elsewhere classified	0.567	0.433	0.000
T44.2 Ganglionic blocking drugs, not elsewhere classified	0.567	0.433	0.000
T44.1 Other parasympathomimetics [cholinergics]	0.567	0.433	0.000
T44.0 Anticholinesterase agents	0.567	0.433	0.000
C85.7 Other specified types of non-Hodgkin's lymphoma	0.000	0.433	0.567
C83.0 Small cell (diffuse)	0.000	0.438	0.562
D65-D69 Coagulation defects, purpura and other haemorrhagic conditions	0.000	0.439	0.561
T36.4 Tetracyclines	0.560	0.440	0.000
C91.9 Lymphoid leukaemia, unspecified	0.000	0.441	0.559
C81.0 Lymphocytic predominance	0.000	0.441	0.559
C90.2 Plasmacytoma, extramedullary	0.000	0.442	0.558
T47.4 Other laxatives	0.552	0.448	0.000
T43.2 Other and unspecified antidepressants	0.551	0.449	0.000
T43.4 Butyrophenone and thioxanthene neuroleptics	0.551	0.449	0.000
E27.9 Disorder of adrenal gland, unspecified	0.000	0.449	0.551
E03.1 Congenital hypothyroidism without goitre	0.000	0.449	0.551
T47.6 Antidiarrhoeal drugs	0.551	0.449	0.000
G36.0 Neuromyelitis optica [Devic]	0.000	0.450	0.550
T39.0 Salicylates	0.547	0.453	0.000
C91.5 Adult T-cell leukaemia	0.000	0.459	0.541
E44 Protein-energy malnutrition of moderate and mild degree	0.000	0.463	0.537
E45 Retarded development following protein-energy malnutrition	0.000	0.463	0.537
E43 Unspecified severe protein-energy malnutrition	0.000	0.463	0.537
E42 Marasmic kwashiorkor	0.000	0.463	0.537
E41 Nutritional marasmus	0.000	0.463	0.537
E40 Kwashiorkor	0.000	0.463	0.537
T50 Poisoning by diuretics and other and unspecified drugs, medicaments and biological substances	0.537	0.463	0.000
C91.0 Acute lymphoblastic leukaemia	0.000	0.464	0.536
E21.3 Hyperparathyroidism, unspecified	0.000	0.464	0.536
D69.2 Other nonthrombocytopenic purpura	0.000	0.464	0.536
C84.5 Other and unspecified T-cell lymphomas	0.000	0.466	0.534
C95 Leukaemia of unspecified cell type	0.000	0.466	0.534
T45.9 Primarily systemic and haematological agent, unspecified	0.533	0.467	0.000
T45.8 Other primarily systemic and haematological agents	0.533	0.467	0.000
T45.7 Anticoagulant antagonists, vitamin K and other coagulants	0.533	0.467	0.000
T45.6 Fibrinolysis-affecting drugs	0.533	0.467	0.000
T45.4 Iron and its compounds	0.533	0.467	0.000
T45.3 Enzymes, not elsewhere classified	0.533	0.467	0.000
E31.0 Autoimmune polyglandular failure	0.000	0.467	0.533
T47.2 Stimulant laxatives	0.533	0.467	0.000
M35.9 Systemic involvement of connective tissue, unspecified	0.000	0.467	0.533
M35.6 Relapsing panniculitis [Weber-Christian]	0.000	0.467	0.533
M35.5 Multifocal fibrosclerosis	0.000	0.467	0.533
M35.4 Diffuse (eosinophilic) fasciitis	0.000	0.467	0.533
E07.9 Disorder of thyroid, unspecified	0.000	0.467	0.533
E05.2 Thyrotoxicosis with toxic multinodular goitre	0.000	0.467	0.532
R30.0 Dysuria	0.529	0.471	0.000
E21.1 Secondary hyperparathyroidism, not elsewhere classified	0.000	0.471	0.529
R30-R39 Symptoms and signs involving the urinary system	0.525	0.475	0.000
G36.9 Acute disseminated demyelination, unspecified	0.000	0.476	0.524
G36.8 Other specified acute disseminated demyelination	0.000	0.476	0.524
G36.1 Acute and subacute haemorrhagic leukoencephalitis [Hurst]	0.000	0.476	0.524
R30 Pain associated with micturition	0.524	0.476	0.000
C93 Monocytic leukaemia	0.000	0.476	0.524
T47.9 Agent primarily affecting the gastro-intestinal system, unspecified	0.523	0.477	0.000
T47.8 Other agents primarily affecting the gastro-intestinal system	0.523	0.477	0.000
T47.7 Emetics	0.523	0.477	0.000
T47.5 Digestants	0.523	0.477	0.000
T47.3 Saline and osmotic laxatives	0.523	0.477	0.000
T47.0 Histamine H(2)-receptor antagonists	0.523	0.477	0.000
M35.8 Other specified systemic involvement of connective tissue	0.000	0.478	0.522
T43.9 Psychotropic drug, unspecified	0.522	0.478	0.000
T43.8 Other psychotropic drugs, not elsewhere classified	0.522	0.478	0.000
E51.9 Thiamine deficiency, unspecified	0.000	0.478	0.522
E51.8 Other manifestations of thiamine deficiency	0.000	0.478	0.522
E51.1 Beriberi	0.000	0.478	0.522
E61.2 Magnesium deficiency	0.000	0.479	0.521
C81.2 Mixed cellularity	0.000	0.481	0.519
E31.9 Polyglandular dysfunction, unspecified	0.000	0.481	0.519
E31.8 Other polyglandular dysfunction	0.000	0.481	0.519
E31.1 Polyglandular hyperfunction	0.000	0.481	0.519
Chapter III Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism	0.000	0.481	0.519
E61.1 Iron deficiency	0.000	0.481	0.519
E00.9 Congenital iodine-deficiency syndrome, unspecified	0.000	0.486	0.514
E00.2 Congenital iodine-deficiency syndrome, mixed type	0.000	0.486	0.514
E00.1 Congenital iodine-deficiency syndrome, myxoedematous type	0.000	0.486	0.514
E00.0 Congenital iodine-deficiency syndrome, neurological type	0.000	0.486	0.514
E01.8 Other iodine-deficiency-related thyroid disorders and allied conditions	0.000	0.486	0.514
E01.2 Iodine-deficiency-related (endemic) goitre, unspecified	0.000	0.486	0.514
E01.1 Iodine-deficiency-related multinodular (endemic) goitre	0.000	0.486	0.514
E01.0 Iodine-deficiency-related diffuse (endemic) goitre	0.000	0.486	0.514
E12.9 Without complications	0.000	0.486	0.514
E12.8 With unspecified complications	0.000	0.486	0.514
E12.7 With multiple complications	0.000	0.486	0.514
E12.6 With other specified complications	0.000	0.486	0.514
E12.5 With peripheral circulatory complications	0.000	0.486	0.514
E12.4 With neurological complications	0.000	0.486	0.514
E12.3 With ophthalmic complications	0.000	0.486	0.514
E12.2 With renal complications	0.000	0.486	0.514
E12.1 With ketoacidosis	0.000	0.486	0.514
E12.0 With coma	0.000	0.486	0.514
E25.0 Congenital adrenogenital disorders associated with enzyme deficiency	0.000	0.486	0.514
E03.2 Hypothyroidism due to medicaments and other exogenous substances	0.000	0.486	0.514
C88 Malignant immunoproliferative diseases	0.000	0.487	0.513
C85.2 Mediastinal (thymic) large B-cell lymphoma	0.000	0.487	0.513
T43.1 Monoamine-oxidase-inhibitor antidepressants	0.512	0.487	0.000
E34.9 Endocrine disorder, unspecified	0.000	0.488	0.512
E25.9 Adrenogenital disorder, unspecified	0.000	0.489	0.511
E25.8 Other adrenogenital disorders	0.000	0.489	0.511
E13 Other specified diabetes mellitus	0.001	0.491	0.508
E30.9 Disorder of puberty, unspecified	0.000	0.491	0.509
E30.8 Other disorders of puberty	0.000	0.491	0.509
E30.1 Precocious puberty	0.000	0.491	0.509
E30.0 Delayed puberty	0.000	0.491	0.509
E32.9 Disease of thymus, unspecified	0.000	0.491	0.509
E32.8 Other diseases of thymus	0.000	0.491	0.509
E32.1 Abscess of thymus	0.000	0.491	0.509
E32.0 Persistent hyperplasia of thymus	0.000	0.491	0.509
E35.8 Disorders of other endocrine glands in diseases classified elsewhere	0.000	0.491	0.509
E35.1 Disorders of adrenal glands in diseases classified elsewhere	0.000	0.491	0.509
E35.0 Disorders of thyroid gland in diseases classified elsewhere	0.000	0.491	0.509
D80-D89 Certain disorders involving the immune mechanism	0.000	0.491	0.509
E21.4 Other specified disorders of parathyroid gland	0.000	0.492	0.508
T48.6 Antiasthmatics, not elsewhere classified	0.505	0.495	0.000
D69.0 Allergic purpura	0.000	0.495	0.505
E61.9 Deficiency of nutrient element, unspecified	0.000	0.497	0.503
E61.8 Deficiency of other specified nutrient elements	0.000	0.497	0.503
E61.7 Deficiency of multiple nutrient elements	0.000	0.497	0.503
E61.6 Vanadium deficiency	0.000	0.497	0.503
E61.5 Molybdenum deficiency	0.000	0.497	0.503
E61.4 Chromium deficiency	0.000	0.497	0.503
E61.3 Manganese deficiency	0.000	0.497	0.503
E61.0 Copper deficiency	0.000	0.497	0.503
T46.3 Coronary vasodilators, not elsewhere classified	0.502	0.498	0.000
T48.5 Anti-common-cold drugs	0.501	0.498	0.000
E55 Vitamin D deficiency	0.000	0.501	0.499
E26.9 Hyperaldosteronism, unspecified	0.000	0.503	0.497
E28 Ovarian dysfunction	0.000	0.504	0.496
E24 Cushing's syndrome	0.000	0.505	0.495
C81.7 Other Hodgkin's disease	0.000	0.505	0.494
C96 Other and unspecified malignant neoplasms of lymphoid, haematopoietic and related tissue	0.000	0.507	0.493
C94 Other leukaemias of specified cell type	0.000	0.507	0.493
T38.3 Insulin and oral hypoglycaemic [antidiabetic] drugs	0.493	0.507	0.000
I20.1 Angina pectoris with documented spasm	0.493	0.507	0.000
E56.1 Deficiency of vitamin K	0.000	0.508	0.491
T36.3 Macrolides	0.491	0.509	0.000
E34.5 Androgen resistance syndrome	0.000	0.512	0.488
E34.4 Constitutional tall stature	0.000	0.512	0.488
E34.2 Ectopic hormone secretion, not elsewhere classified	0.000	0.512	0.488
E34.1 Other hypersecretion of intestinal hormones	0.000	0.512	0.488
C91.8 Mature B-cell leukaemia Burkitt-type	0.000	0.513	0.487
C91.7 Other lymphoid leukaemia	0.000	0.513	0.487
C91.6 Prolymphocytic leukaemia of T-cell type	0.000	0.513	0.487
C91.3 Prolymphocytic leukaemia	0.000	0.513	0.487
C91.2 Subacute lymphocytic leukaemia	0.000	0.513	0.487
E07.1 Dyshormogenetic goitre	0.000	0.514	0.486
E07.0 Hypersecretion of calcitonin	0.000	0.514	0.486
C81.4 Lymphocyte-rich classical Hodgkin lymphoma	0.000	0.515	0.485
C81.3 Lymphocytic depletion	0.000	0.515	0.485
E56.9 Vitamin deficiency, unspecified	0.000	0.515	0.485
E56.8 Deficiency of other vitamins	0.000	0.515	0.485
E56.0 Deficiency of vitamin E	0.000	0.515	0.485
E34.3 Short stature, not elsewhere classified	0.000	0.515	0.485
C85.0 Lymphosarcoma	0.000	0.517	0.483
E21.2 Other hyperparathyroidism	0.000	0.518	0.482
E34.8 Other specified endocrine disorders	0.000	0.518	0.482
T36.9 Systemic antibiotic, unspecified	0.482	0.518	0.000
T36.8 Other systemic antibiotics	0.482	0.518	0.000
T36.7 Antifungal antibiotics, systemically used	0.482	0.518	0.000
T36.6 Rifamycins	0.482	0.518	0.000
T36.5 Aminoglycosides	0.482	0.518	0.000
T36.2 Chloramphenicol group	0.482	0.518	0.000
T36.1 Cefalosporins and other Beta-lactam antibiotics	0.482	0.518	0.000
E50.9 Vitamin A deficiency, unspecified	0.000	0.519	0.481
E50.8 Other manifestations of vitamin A deficiency	0.000	0.519	0.481
E50.7 Other ocular manifestations of vitamin A deficiency	0.000	0.519	0.481
E50.6 Vitamin A deficiency with xerophthalmic scars of cornea	0.000	0.519	0.481
E50.5 Vitamin A deficiency with night blindness	0.000	0.519	0.481
E50.4 Vitamin A deficiency with keratomalacia	0.000	0.519	0.481
E50.3 Vitamin A deficiency with corneal ulceration and xerosis	0.000	0.519	0.481
E50.2 Vitamin A deficiency with corneal xerosis	0.000	0.519	0.481
E50.1 Vitamin A deficiency with Bitot's spot and conjunctival xerosis	0.000	0.519	0.481
E50.0 Vitamin A deficiency with conjunctival xerosis	0.000	0.519	0.481
E63.9 Nutritional deficiency, unspecified	0.000	0.519	0.481
E63.8 Other specified nutritional deficiencies	0.000	0.519	0.481
E63.1 Imbalance of constituents of food intake	0.000	0.519	0.481
E63.0 Essential fatty acid [EFA] deficiency	0.000	0.519	0.481
E64.9 Sequelae of unspecified nutritional deficiency	0.000	0.519	0.481
E64.8 Sequelae of other nutritional deficiencies	0.000	0.519	0.481
E64.3 Sequelae of rickets	0.000	0.519	0.481
E64.2 Sequelae of vitamin C deficiency	0.000	0.519	0.481
E64.1 Sequelae of vitamin A deficiency	0.000	0.519	0.481
E64.0 Sequelae of protein-energy malnutrition	0.000	0.519	0.481
T48.7 Other and unspecified agents primarily acting on the respiratory system	0.475	0.525	0.000
T48.4 Expectorants	0.475	0.525	0.000
T48.3 Antitussives	0.475	0.525	0.000
T48.2 Other and unspecified agents primarily acting on muscles	0.475	0.525	0.000
T48.1 Skeletal muscle relaxants [neuromuscular blocking agents]	0.475	0.525	0.000
T48.0 Oxytocic drugs	0.475	0.525	0.000
E65-E68 Obesity and other hyperalimentation	0.000	0.525	0.475
D69.8 Other specified haemorrhagic conditions	0.000	0.526	0.474
T45.5 Anticoagulants	0.472	0.528	0.000
C92 Myeloid leukaemia	0.000	0.529	0.471
E26.8 Other hyperaldosteronism	0.000	0.531	0.469
E26.1 Secondary hyperaldosteronism	0.000	0.531	0.469
I20.9 Angina pectoris, unspecified	0.469	0.531	0.000
C86 Other specified types of T/NK-cell lymphoma	0.000	0.533	0.467
C84.4 Peripheral T-cell lymphoma	0.000	0.533	0.467
D69.9 Haemorrhagic condition, unspecified	0.000	0.535	0.465
R34 Anuria and oliguria	0.465	0.535	0.000
M35.2 Behcet's disease	0.000	0.539	0.461
E15 Nondiabetic hypoglycaemic coma	0.000	0.540	0.460
E22 Hyperfunction of pituitary gland	0.000	0.541	0.459
C84.8 Cutaneous T-cell lymphoma, unspecified	0.000	0.542	0.458
I23.8 Other current complications following acute myocardial infarction	0.451	0.548	0.000
D80 Immunodeficiency with predominantly antibody defects	0.000	0.549	0.451
N20.0 Calculus of kidney	0.450	0.550	0.000
D69.1 Qualitative platelet defects	0.000	0.551	0.449
T39.8 Other nonopioid analgesics and antipyretics, not elsewhere classified	0.447	0.553	0.000
D86 Sarcoidosis	0.000	0.554	0.446
D50-D53 Nutritional anaemias	0.000	0.556	0.444
C83.7 Burkitt's tumour	0.000	0.557	0.443
T38.9 Other and unspecified hormone antagonists	0.443	0.557	0.000
T38.7 Androgens and anabolic congeners	0.443	0.557	0.000
T38.5 Other oestrogens and progestogens	0.443	0.557	0.000
T38.4 Oral contraceptives	0.443	0.557	0.000
T38.2 Antithyroid drugs	0.443	0.557	0.000
T38.0 Glucocorticoids and synthetic analogues	0.443	0.557	0.000
T36.0 Penicillins	0.442	0.558	0.000
C90.1 Plasma cell leukaemia	0.000	0.558	0.442
E34.0 Carcinoid syndrome	0.000	0.559	0.440
I23.6 Thrombosis of atrium, auricular appendage and ventricle as current complications following acute myocardial infarction	0.439	0.561	0.000
I23.5 Rupture of papillary muscle as current complication following acute myocardial infarction	0.439	0.561	0.000
I23.4 Rupture of chordae tendineae as current complication following acute myocardial infarction	0.439	0.561	0.000
I23.3 Rupture of cardiac wall without haemopericardium as current complication following acute myocardial infarction	0.439	0.561	0.000
I23.2 Ventricular septal defect as current complication following acute myocardial infarction	0.439	0.561	0.000
I23.1 Atrial septal defect as current complication following acute myocardial infarction	0.439	0.561	0.000
I23.0 Haemopericardium as current complication following acute myocardial infarction	0.439	0.561	0.000
E29.9 Testicular dysfunction, unspecified	0.000	0.561	0.438
E29.8 Other testicular dysfunction	0.000	0.561	0.438
E29.0 Testicular hyperfunction	0.000	0.561	0.438
T41.5 Therapeutic gases	0.438	0.562	0.000
T41.4 Anaesthetic, unspecified	0.438	0.562	0.000
T41.3 Local anaesthetics	0.438	0.562	0.000
T41.2 Other and unspecified general anaesthetics	0.438	0.562	0.000
T41.1 Intravenous anaesthetics	0.438	0.562	0.000
T41.0 Inhaled anaesthetics	0.438	0.562	0.000
T49.9 Topical agent, unspecified	0.438	0.562	0.000
T49.8 Other topical agents	0.438	0.562	0.000
T49.7 Dental drugs, topically applied	0.438	0.562	0.000
T49.6 Otorhinolaryngological drugs and preparations	0.438	0.562	0.000
T49.5 Ophthalmological drugs and preparations	0.438	0.562	0.000
T49.4 Keratolytics, keratoplastics and other hair treatment drugs and preparations	0.438	0.562	0.000
T49.3 Emollients, demulcents and protectants	0.438	0.562	0.000
T49.2 Local astringents and local detergents	0.438	0.562	0.000
T49.1 Antipruritics	0.438	0.562	0.000
T49.0 Local antifungal, anti-infective and anti-inflammatory drugs, not elsewhere classified	0.438	0.562	0.000
D86.9 Sarcoidosis, unspecified	0.000	0.564	0.436
C84.9 Mature T/NK-cell lymphoma, unspecified	0.000	0.564	0.436
C84.7 Anaplastic large cell lymphoma, ALK-negative	0.000	0.564	0.436
C84.6 Anaplastic large cell lymphoma, ALK-positive	0.000	0.564	0.436
C84.3 Lymphoepithelioid lymphoma	0.000	0.564	0.436
C84.2 T-zone lymphoma	0.000	0.564	0.436
C84.1 Sezary's diease	0.000	0.564	0.436
D89 Other disorders involving the immune mechanism, not elsewhere classified	0.000	0.565	0.435
C95.0 Acute leukaemia of unspecified cell type	0.000	0.567	0.433
T38.8 Other and unspecified hormones and their synthetic substitutes	0.432	0.567	0.000
E21.0 Primary hyperparathyroidism	0.000	0.570	0.430
R35 Polyuria	0.429	0.571	0.000
E21.5 Disorder of parathyroid gland, unspecified	0.000	0.573	0.427
T45.2 Vitamins, not elsewhere classified	0.425	0.575	0.000
D55-D59 Haemolytic anaemias	0.000	0.575	0.425
T38.1 Thyroid hormones and substitutes	0.424	0.576	0.000
T37.9 Systemic anti-infective and antiparasitic, unspecified	0.423	0.577	0.000
T37.5 Antiviral drugs	0.423	0.577	0.000
T37.4 Anthelminthics	0.423	0.577	0.000
T37.3 Other antiprotozoal drugs	0.423	0.577	0.000
T37.2 Antimalarials and drugs acting on other blood protozoa	0.423	0.577	0.000
T37.1 Antimycobacterial drugs	0.423	0.577	0.000
T37.0 Sulphonamides	0.423	0.577	0.000
T42 Poisoning by antiepileptic, sedative-hypnotic and anti-Parkinsonism drugs	0.423	0.577	0.000
I24.1 Dressler's syndrome	0.421	0.578	0.000
C90.3 Solitary plasmacytoma	0.000	0.578	0.421
C84.0 Mycosis fungoides	0.000	0.580	0.420
D65 Disseminated intravascular coagulation [defibrination syndrome]	0.000	0.580	0.420
N20 Calculus of kidney and ureter	0.417	0.583	0.000
T38.6 Antigonadotrophins. antioestrogens, antiandrogens, not elsewhere classified	0.416	0.584	0.000
D84 Other immunodeficiencies	0.000	0.586	0.414
N20.1 Calculus of ureter	0.413	0.587	0.000
C83.6 Undifferentiated (diffuse)	0.000	0.587	0.413
C83.5 Lymphoblastic (diffuse)	0.000	0.587	0.413
C83.4 Immunoblastic (diffuse)	0.000	0.587	0.413
C83.2 Mixed small and large cell (diffuse)	0.000	0.587	0.413
T50.2 Carbonic-anhydrase inhibitors, benzothiadiazides and other diuretics	0.411	0.589	0.000

This table lists the top 500 terms ordered by p(effect).

The full results table can be downloaded from this page.

The TreeWAS Database is the result of research conducted at the Oxford Big Data Institute at the University of Oxford.

This research has been conducted using the UK Biobank Resource (application number 10625). This work uses data provided by patients and collected by the NHS as part of their care and support.

This research has been conducted with the support of the Wellcome Trust (100956/Z/13/Z and 090532/Z/09/Z and 100308/Z/12/Z), the Danish National Research Foundation, Takeda, the Medical Research Council (MC_UU_12010/3), the Oak Foundation (OCAY-15-520), the National Institute for Health Research (NIHR) Oxford Biomedical Research Centre (BRC), the Wellcome Trust/Royal Society (204290/Z/16/Z) and the Li Ka Shing Foundation.

Variant-specific associations